Gastrointestinal ReProgramming (GaRP) complementary medicine
Anatara is seeking to partner with international pharmaceutical and consumer health companies for the commercialisation of its Gastrointestinal ReProgramming (GaRP) dietary supplement product which has been designed to address the primary underlying factors associated with human gastrointestinal conditions such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), where there is a significant unmet need and market opportunity. In February 2019, Anatara announced breakthrough positive efficacy data from its in vitro Proof of Concept studies of its GaRP dietary supplement product in both reducing inflammation and restoring gut integrity. Further information can be found here. With preclinical development successfully completed (further information can be found here), recruitment for a clinical trial in subjects with IBS-D commenced in August 2021.
3FDC (3 components with functional delivery coating) complementary medicine
3FDC has been designed so coated components are released in the large intestine (colon) to positively influence the gut-brain connection, targeting modulation of psychobiological processes driving anxiety-related disorders and to assist homeostasis of the “gut” to promote overall health and wellbeing. The formulation combines synergistic, generally regarded as safe (GRAS) ingredients. A psychological functioning trial of 3FDC commenced in mid-February 2022 in subjects with moderate levels of depression, anxiety, or stress symptoms indicated by the Depression, Anxiety and Stress Scale (DASS-21).
Detach® For Pigs and other Livestock
Anatara developed Detach® initially for the control of scour (diarrhoea) in pigs. In October 2018, the Australian Pesticides and Veterinary Medicines Authority (APVMA) registered Detach® for this application. Anatara is seeking interest from international animal health companies in licensing Detach® for use in pigs in Australia and/or overseas markets. APVMA registration may provide an opportunity to fast track regulatory product registration in particular South Asia markets. Anatara is also seeking interest from international animal health companies in licensing Detach® to develop for use in other livestock species such as poultry. Opportunities exist for the development of new formulations and administration methods for Detach® to expand utility of the product.
Anatara is exploring partnering opportunities for the licencing of Detach® and/or GaRP for use in companion animals where diarrhoea remains a common health concern in dogs and cats.
To discuss opportunities to partner with Anatara on our programs, please contact:
Michael Pryor, Head of Business Development & Marketing Communications
M: +61 437 132 122